Naoki Sakuyama

Dr. Naoki Sakuyama

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2019 in Cancer Science
Verified
Journal Article
Open access
PDF file
KIKen Imaizumi
Ken Imaizumi
TSToshihiro Suzuki
Toshihiro Suzuki
MKMotohiro Kojima
Motohiro Kojima
MSManami Shimomura
Manami Shimomura
NSNaoki Sakuyama
Naoki Sakuyama
TNTetsuya Nakatsura
Tetsuya Nakatsura
Chemoradiotherapy (CRT) is the standard neoadjuvant therapy for locally advanced rectal cancer (RC). However, neoadjuvant chemotherapy (NAC) also shows favorable outcomes. Although the immunological environment of RC has been thoroughly discussed, the effect of NAC on it is less clear. Here, we investigated the immunological microenvironment, including T cell infiltration, activation, and topological distribution, of resected RC tissue after neoadjuvant therapies and evaluated the correlation between T cell subsets and patient prognosis. Rectal cancer patients (n = 188) were enrolled and categorized into 3 groups, namely CRT (n = 41), NAC (n = 46), and control (surgery alone; n = 101) groups. Characterization of residual carcinoma cells and T cell subsets in resected tissues was performed using multiplex fluorescence immunohistochemistry. The densities of total and activated (Ki67high) T cells in tissues after NAC, but not CRT, were higher than in control. In both CRT and NAC groups, patients presenting with higher treatment effects showed aggressive infiltration of T cell subsets into carcinomas. Multivariate analyses of pathological and immunological features and prognosis revealed that carcinoma Ki67highCD4+ T cells after CRT and stromal Ki67highCD8+ T cells after NAC are important prognostic factors, respectively. Our results suggest that evaluation of T cell activation with Ki67 expression and its tumor localization can be used to determine the prognosis of advanced RC after neoadjuvant therapies.

1 February 2018 in Cancer Science
Verified
Journal Article
Open access
PDF file
NSNaoki Sakuyama
Naoki Sakuyama
MKMotohiro Kojima
Motohiro Kojima
SKShingo Kawano
Shingo Kawano
YMYoko Matsuda
Yoko Matsuda
MMMari Mino‐Kenudson
Mari Mino‐Kenudson
MIMasaaki Ito
Masaaki Ito
The aim of this study was to elucidate differences in the histological features of rectal cancer between patients treated with preoperative chemoradiotherapy and those treated with preoperative chemotherapy. Area of residual tumor (ART) was also evaluated for its utility as a potential prognostic marker between them. Sixty‐eight patients with rectal cancer who underwent sphincter‐saving surgery were enrolled in this study. Of these, 39 patients received preoperative chemoradiotherapy (CRT group) and 29 patients received preoperative (neoadjuvant) chemotherapy (NAC group). Area of residual tumor was determined by using morphometric software. Tumors in the two groups were compared for differences in their histological features and clinical outcomes. Tumors in the CRT and NAC groups varied greatly with regard to their histological features after preoperative therapy. Tumors in the CRT group showed more marked fibrosis than those in the NAC group. The total ART were significantly smaller in tumors in the CRT group than those in the NAC group. However, in circumferential resection margin‐negative pathologic stage 0‐III cases, clinical outcomes were not statistically different between the CRT and NAC groups. Both ART and pathologic TNM classification were associated with clinical outcome in preoperative CRT and NAC groups, but Dworak regression grade and fibrotic change were not. Tumors in those undergoing preoperative CRT and NAC were shown to differ significantly in their histological features. Area of residual tumor‐based assessment may provide useful prognostic information, regardless of preoperative therapy.

30 June 2023 in American Journal of Surgical Pathology
Verified
Journal Article
Open access
MKMotohiro Kojima
Motohiro Kojima
MYMitsuru Yokota
Mitsuru Yokota
NYNaotake Yanagisawa
Naotake Yanagisawa
SKSakiko Bsc Kitamura
Sakiko Bsc Kitamura
KAKota Amemiya
Kota Amemiya
AOAtsushi Ochiai
Atsushi Ochiai
The extent of tumor spread influences on the clinical outcome, and which determine T stage of colorectal cancer. However, pathologic discrimination between pT3 and pT4a in the eighth edition of the American Joint Committee on Cancer (AJCC)-TNM stage is subjective, and more objective discrimination method for deeply invasive advanced colon cancer is mandatory for standardized patient management. Peritoneal elastic laminal invasion (ELI) detected using elastic staining may increase the objective discrimination of deeply invasive advanced colon cancer. In this study, we constructed ELI study group to investigate feasibility, objectivity, and prognostic utility of ELI. Furthermore, pT classification using ELI was investigated based on these data. At first, concordance study investigated objectivity using 60 pT3 and pT4a colon cancers. Simultaneously, a multi-institutional retrospective study was performed to assess ELI’s prognostic utility in 1202 colon cancer cases from 6 institutions. In the concordance study, objectivity, represented by κ, was higher in the ELI assessment than in pT classification. In the multi-institutional retrospective study, elastic staining revealed that ELI was a strong prognostic factor. The clinical outcome of pT3 cases with ELI was significantly and consistently worse than that of those without ELI. pT classification into pT3 without ELI, pT3 with ELI, and pT4a was an independent prognostic factor. In this study, we revealed that ELI is an objective method for discriminating deeply invasive advanced colon cancer. Based on its feasibility, objectivity, and prognostic utility, ELI can subdivide pT3 lesions into pT3a (without ELI) and pT3b (with ELI).

23 October 2024 in Sports
Verified
Journal Article
Open access
PDF file
AIAkira Ikumi
Akira Ikumi
ESEiji Sasaki
Eiji Sasaki
NSNaoki Sakuyama
Naoki Sakuyama
YMYasuo Mikami
Yasuo Mikami
Elbow injuries are common in judo, particularly among adolescents. This study investigated the incidence and patterns of three types of elbow injuries (sprain, dislocation, and fracture-dislocation) among Japanese adolescent judo players (12 to 18 years old) using data from a nationwide insurance database, covering the period from 2010 to 2019. A total of 4614 elbow injuries were recorded, with sprains being the most frequent (67.6% of cases). Female players had a 20% higher incidence of sprains than male players (6.8 vs. 5.4 per 1000 athlete-years). Severe injuries, such as dislocations and fracture-dislocations, were more common in high school players, with male middle school students exhibiting a higher rate of elbow fracture-dislocations (+15%) compared with female students. Elbow injuries frequently occurred during te-waza techniques, particularly seoi-nage, when players extended their arms to prevent being thrown. Peripheral nerve injuries, predominantly ulnar nerve injuries, accompanied elbow dislocations in 74% of the cases. This study highlights the importance of proper instruction in defensive and ukemi techniques, particularly those that discourage the use of hands to prevent falls during throws, to reduce the risk of elbow injuries.

1 January 2019 in Juntendo Medical Journal
Verified
Journal Article
Open access
PDF file
KSKiichi Sugimoto
Kiichi Sugimoto
TYTakeshi Yamada
Takeshi Yamada
SIShun Ishiyama
Shun Ishiyama
MNMasato Nakamura
Masato Nakamura
YYYoichiro Yoshida
Yoichiro Yoshida
KSKazuhiro Sakamoto
Kazuhiro Sakamoto
Objective: Regorafenib (BAY 73-4506) is an oral multikinase inhibitor that has been shown to inhibit various oncogenic stromal receptor tyrosine kinases and intracellular signaling kinase. The aim of the study is to confirm the safety and effectiveness of dose escalation therapy of regorafenib for the third- or fourth- treatments of patients with unresectable and recurrent colorectal cancer.Design: This study is designed as a single-arm, prospective, non-randomized, multi-centered open label phase II trial in Japan. The study regimen consists of 28-day cycles with escalated doses of regorafenib (80-160 mg/body on days 1 to 21). This study is a dose-escalation study using a starting dose of 80 mg/day during the first seven days. In case of no adverse events related to the administration after the first seven days of the starting dose, the administration dose will be increased to 120 mg/day on days 8 to 14. The administration dose will then be increased to 160 mg/day on days 15 to 21. Primary end point is progression free survival (PFS); secondary end points include time to treatment failure, response rate, overall survival, the interval between the initial of drug administration and performance status 2, the transition rate to the following line of treatment, the cumulative dose and the incidence of adverse events of grade 3 or higher, and genetic alterations (KRAS mutation/BRAF mutation) in circulating cell-free DNA.Conclusions: This study may contribute to determining the efficacy of the escalation of the administration dose in patients with metastatic colorectal cancer.

25 June 2026 in Clinical Journal of Sport Medicine
Verified
Journal Article
Closed access
KSKabir Singh
Kabir Singh
NMNikos Malliaropoulos
Nikos Malliaropoulos
MCMike Callan
Mike Callan
TKTakeshi Kamitani
Takeshi Kamitani
AIAkira Ikumi
Akira Ikumi
Nicola MaffulliNicola Maffulli
Nicola Maffulli